Announcement of the expiration of the Company's 2024 cash capital increase call period and the issuance of stocks

Announcement on behalf of OBIGEN that it has filed the application of repeat-dose Phase II safety study for OBI-858 to TFDA

OBI is invited to present the current development status of its products and technology platforms at the investor conference hosted by MasterLink

Announcement of the Company's full receipt of cash capital increase in 2024 and the reference date of capital increase

Subscription rights to the cash issue forfeited by directors of the Company reaching 50% and subscription being made available to specific persons

Announcement of calls on unpaid shares of 2024 cash capital increase

Announcement of the Consolidated Financial Statements for the third quarter of 2024 were approved by the Board of Directors.

Announcement of the Company’s board meeting date to approve 2024Q3 consolidated financial report

Announcement of issue price and banks designated to collect and deposit the proceeds for 2024 cash capital increase

Announcement on behalf of OBIGEN of the Board’s resolution to lift the non-competition restrictions for CEO